Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a Phase 1, open-label study of SH-1028 with dose escalation and dose expansion cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent.
Epistemonikos ID: 4e2d25f87b622ae0e6616139ba9b0fa9263c49a9
First added on: May 21, 2024